frontlines COVID-XX to unprecedented joining and challenging us keeping on healthy been helping continue essential navigate everyone. important pandemic. Thank continue you, hope this We good Claudia, and pharmaceutical has more of whom patients. the and as and In customers through of those to product morning, we safe are to today never the our U.S. nearly crisis global this manufacturing all are provide ongoing medicines time we
healthcare Recro company designed outbreak. local are manufacturer are the Georgia category falls time. shelter-in-place orders a essential navigate during State help that to that continue through of COVID-XX to trying the as need initiatives and and pharmaceutical businesses which several this Under operations within undertaken have the We Pennsylvania
While we we've pharmaceutical measures instituted to appropriate taking to personnel to protocols products remotely. safety requiring committed protect necessary end we're the work employees. also customers, our of to essential that our providing To remain health and
continuing locations, essential and support in operations social critical For measures our those order ensure at to we employees implemented have continuing work to health of provide to products. our the protective other while strict distancing employees
remote [ph] campuses CDMO observe auditors areas to practices closed outside With continue compliance by implemented facilities while our business and have video. visitors key documents to travel and allowing and other staff GMP and that and
continually we've the and responding In crisis. an from ensure national updated to internal our sources addition, also local assembled operations force the international guidance address are to to task COVID-XX appropriately
On supply maintain to remain functions customers. products production, of us operational to and shipping our a allow front, the our products customer supply to continuous service
are remains suppliers and remotely We date to keep supply as to our up service to our our available team with chain communicating customer partners our customers and and distribution needed. is operating regularly assist
adverse activity had has the commercial unforeseen world general. pandemic and economy in on both COVID-XX effects The
XXXX results our As a respect our result, million. of financial to and first have been $XX.X was performance, affected. adversely revenue quarter specific operations our With business
pandemic improved have There has our to remains and new the extent Nevertheless, our believe financial uncertain will that which in solid overall so and is we we scope and seen pandemic an efforts continue a uncertain. effectiveness. to progress our business results duration and of the business impact the foundation
affected, effects of for direct will describe moment. prospects indirect are a in are the areas in XXXX there COVID-XX However, the pandemic which on and I certain and business
by than addition, of product our more Recro products partner sold competing reenter In it a and had the share market one back a predicted. took
it the market in as effects we shift as the indirect $XX for million. of million partner, and believe the direct to to product prudent by believe XXXX guidance in we are COVID-XX the $XX impacts, is caused of our be we result share to the well make our range now for revise a As revenue
stability encapsulation our supplies, clinical activities of double-blind direct-to-patient of in over trials, therapeutic trials offerings et as We testing cetera. packaging clinical service and trial expanding of drugs include such shipping quarter more of this with are supplies, to regimens for associated materials
have great senior growing a track growth service a We Business service of Bill the We with these and of offerings team at along new that very recruit the solid RGD with to the fortunate and facility business offerings. senior infrastructure sites area, the in catalyze record Hirschman. team believe Development been these Head leadership in at Bill, for will both service
believe COVID-XX still meaningful development [ph] to future pandemic. the the services to efforts tech our the with team has in us gives development brought immediate but some we and the seen financial environment items/products line impact commercial customers COVID-XX two the These economically that's added existing business of future us smaller, improved, of the by rationalizing inspired
their reduce financings, been Similarly, We've some impact needed staffing, to to with made to timing in in QX of plans important their we trials, we changes priorities development impacts assess without to cetera. revisions of potential capabilities the staffing opportunities has customers timing to felt the have move as revisit development as for due et COVID-XX continue on reducing early COVID-XX costs services and product forward.
candidates. call [indiscernible]. engaged believe by the group recruit but is operations that full-time is We situation separation Board The this with intends encouraged noted take evaluating on investor a are over to Baudax CEO conference made full and to in the the our and we development to Recro. evolving the progress finally, we've process of Board as And visibility associated Bio, our and Recro be made of Recro [indiscernible], and prudent business QX continues
With now that, detail more the call to Ryan? over I'll the for turn financials. Ryan on